QPCTL regulates macrophage and monocyte abundance and inflammatory signatures in the tumor microenvironment

por Bresser, Kaspar, Logtenberg, Meike E. W., Toebes, Mireille, Proost, Natalie, Sprengers, Justin, Siteur, Bjorn, Boeije, Manon, Kroese, Lona J., Schumacher, Ton N.
Publicado 2022

Ezh2 inhibition in Kras-driven lung cancer amplifies inflammation and associated vulnerabilities

por Serresi, Michela, Siteur, Bjorn, Hulsman, Danielle, Company, Carlos, Schmitt, Matthias J., Lieftink, Cor, Morris, Ben, Cesaroni, Matteo, Proost, Natalie, Beijersbergen, Roderick L., van Lohuizen, Maarten, Gargiulo, Gaetano
Publicado 2018

Modeling invasive lobular breast carcinoma by CRISPR/Cas9-mediated somatic genome editing of the mammary gland

por Annunziato, Stefano, Kas, Sjors M., Nethe, Micha, Yücel, Hatice, Del Bravo, Jessica, Pritchard, Colin, Bin Ali, Rahmen, van Gerwen, Bas, Siteur, Bjørn, Drenth, Anne Paulien, Schut, Eva, van de Ven, Marieke, Boelens, Mirjam C., Klarenbeek, Sjoerd, Huijbers, Ivo J., van Miltenburg, Martine H., Jonkers, Jos
Publicado 2016

Comparative oncogenomics identifies combinations of driver genes and drug targets in BRCA1-mutated breast cancer

por Annunziato, Stefano, de Ruiter, Julian R., Henneman, Linda, Brambillasca, Chiara S., Lutz, Catrin, Vaillant, François, Ferrante, Federica, Drenth, Anne Paulien, van der Burg, Eline, Siteur, Bjørn, van Gerwen, Bas, de Bruijn, Roebi, van Miltenburg, Martine H., Huijbers, Ivo J., van de Ven, Marieke, Visvader, Jane E., Lindeman, Geoffrey J., Wessels, Lodewyk F. A., Jonkers, Jos
Publicado 2019

Combined inhibition of EZH2 and ATM is synthetic lethal in BRCA1-deficient breast cancer

por Ratz, Leonie, Brambillasca, Chiara, Bartke, Leandra, Huetzen, Maxim A., Goergens, Jonas, Leidecker, Orsolya, Jachimowicz, Ron D., van de Ven, Marieke, Proost, Natalie, Siteur, Bjørn, de Korte-Grimmerink, Renske, Bouwman, Peter, Pulver, Emilia M., de Bruijn, Roebi, Isensee, Jörg, Hucho, Tim, Pandey, Gaurav, van Lohuizen, Maarten, Mallmann, Peter, Reinhardt, Hans Christian, Jonkers, Jos, Puppe, Julian
Publicado 2022

Division of labor within the DNA damage tolerance system reveals non-epistatic and clinically actionable targets for precision cancer medicine

por Spanjaard, Aldo, Shah, Ronak, de Groot, Daniël, Buoninfante, Olimpia Alessandra, Morris, Ben, Lieftink, Cor, Pritchard, Colin, Zürcher, Lisa M, Ormel, Shirley, Catsman, Joyce J I, de Korte-Grimmerink, Renske, Siteur, Bjørn, Proost, Natalie, Boadum, Terry, van de Ven, Marieke, Song, Ji-Ying, Kreft, Maaike, van den Berk, Paul C M, Beijersbergen, Roderick L, Jacobs, Heinz
Publicado 2022

MYC is a clinically significant driver of mTOR inhibitor resistance in breast cancer

por Bhin, Jinhyuk, Yemelyanenko, Julia, Chao, Xue, Klarenbeek, Sjoerd, Opdam, Mark, Malka, Yuval, Hoekman, Liesbeth, Kruger, Dinja, Bleijerveld, Onno, Brambillasca, Chiara S., Sprengers, Justin, Siteur, Bjørn, Annunziato, Stefano, van Haren, Matthijs J., Martin, Nathaniel I., van de Ven, Marieke, Peters, Dennis, Agami, Reuven, Linn, Sabine C., Boven, Epie, Altelaar, Maarten, Jonkers, Jos, Zingg, Daniel, Wessels, Lodewyk F.A.
Publicado 2023

Truncated FGFR2 is a clinically actionable oncogene in multiple cancers

por Zingg, Daniel, Bhin, Jinhyuk, Yemelyanenko, Julia, Kas, Sjors M., Rolfs, Frank, Lutz, Catrin, Lee, Jessica K., Klarenbeek, Sjoerd, Silverman, Ian M., Annunziato, Stefano, Chan, Chang S., Piersma, Sander R., Eijkman, Timo, Badoux, Madelon, Gogola, Ewa, Siteur, Bjørn, Sprengers, Justin, de Klein, Bim, de Goeij-de Haas, Richard R., Riedlinger, Gregory M., Ke, Hua, Madison, Russell, Drenth, Anne Paulien, van der Burg, Eline, Schut, Eva, Henneman, Linda, van Miltenburg, Martine H., Proost, Natalie, Zhen, Huiling, Wientjens, Ellen, de Bruijn, Roebi, de Ruiter, Julian R., Boon, Ute, de Korte-Grimmerink, Renske, van Gerwen, Bastiaan, Féliz, Luis, Abou-Alfa, Ghassan K., Ross, Jeffrey S., van de Ven, Marieke, Rottenberg, Sven, Cuppen, Edwin, Chessex, Anne Vaslin, Ali, Siraj M., Burn, Timothy C., Jimenez, Connie R., Ganesan, Shridar, Wessels, Lodewyk F. A., Jonkers, Jos
Publicado 2022

Publisher Correction: Truncated FGFR2 is a clinically actionable oncogene in multiple cancers

por Zingg, Daniel, Bhin, Jinhyuk, Yemelyanenko, Julia, Kas, Sjors M., Rolfs, Frank, Lutz, Catrin, Lee, Jessica K., Klarenbeek, Sjoerd, Silverman, Ian M., Annunziato, Stefano, Chan, Chang S., Piersma, Sander R., Eijkman, Timo, Badoux, Madelon, Gogola, Ewa, Siteur, Bjørn, Sprengers, Justin, de Klein, Bim, de Goeij-de Haas, Richard R., Riedlinger, Gregory M., Ke, Hua, Madison, Russell, Drenth, Anne Paulien, van der Burg, Eline, Schut, Eva, Henneman, Linda, van Miltenburg, Martine H., Proost, Natalie, Zhen, Huiling, Wientjens, Ellen, de Bruijn, Roebi, de Ruiter, Julian R., Boon, Ute, de Korte-Grimmerink, Renske, van Gerwen, Bastiaan, Féliz, Luis, Abou-Alfa, Ghassan K., Ross, Jeffrey S., van de Ven, Marieke, Rottenberg, Sven, Cuppen, Edwin, Chessex, Anne Vaslin, Ali, Siraj M., Burn, Timothy C., Jimenez, Connie R., Ganesan, Shridar, Wessels, Lodewyk F. A., Jonkers, Jos
Publicado 2022